| ATCT Main | Editorial Board | Current Issue | Infocus Roundtable | ATCT CME Activities | Download | Search |
Search previous issues of ATCT:
Search the web:
Therapeutic Vaccines for Non-Small-Cell Lung Cancer–Success on the Horizon?
Texas Researchers Advance New Understanding of Cell Death
Angiogenesis Inhibitor-Associated Hypertension: Is it Real? How Should it be Managed?
Half of All Cancer Deaths Can Be Prevented
News From the 97th AACR Annual Meeting
Panitumumab Improves Progression-Free Survival in Metastatic Colorectal Cancer
Celecoxib: Preventative Effects, But High CV Risk, in Colorectal Cancer
NCI Researchers Find New Way to Identify Potential Anticancer Targets
Other News
Investigators Explore Expanding Uses for Bortezomib
Managing EGFR Inhibitor-Associated Rash
American Lung Association Reports 2005 Progress in Tobacco Control
News From the 47th Annual Meeting of the American Society of Hematology (December 2005)
Imatinib Continues to Reduce Residual CML-CP After 4 Years in Early Responders
Lestaurtinib Boosts Effect of Standard Chemotherapy in Relapsed AML
Other News
Glycoprotein A34 Under Exploration As Possible Cancer Target
Erlotinib Offers Survival Benefit & Other Advantages in NSCLC
Many Americans Believe Common Cancer Misconceptions
News From the 11th World Conference on Lung Cancer (July 2005)
ZD6474 Improves Time to Cancer Progression in Recurrent NSCLC
Erlotinib Effective in the Elderly and Patients With Bronchioalveolar Cancer
Studies of Novel Targeted Agents Suggest Potential in Cancer Therapy
Other News
Targeting Genes With Radiation
Platelet-Derived Growth Factor Receptor (PDGFR): Another New Target for Anticancer Therapies?
Viruses and Other Substances Added to List of Cancer-Causing Substances
News From the 2005 American Society of Clinical Oncology (ASCO) Annual Meeting (May 2005)
Addition of Bevacizumab to Chemotherapy Considered an Advance in NSCLC Treatment
Sorafenib Provides Survival Advantage Over Placebo in Renal Cell Carcinoma Patients
Study Identifies Factors Predicting Gefitinib Efficacy in NSCLC Patients
Matuzumab Promising for Advanced Cervical Cancer After Chemotherapy Failure
Mining the Cancer Genome: Identifying New Targets for Existing Treatments
Cancer or Heart Disease? Competing for Top Billing as #1 Killer
News from ASH
News from 2nd Annual Gastrointestinal Cancers Symposium
Bevacizumab Improves Efficacy of Chemotherapy Regimens in GI Malignancies
Addition of Erlotinib to Chemotherapy Improves Survival in Advanced Pancreatic Cancer
Progress in Targeted Cancer Therapies: Simultaneous Inhibition
of Multiple Receptors
Changing the Way Science Does Business
Lung Cancer Update
Other News
Virotherapy: Harnessing Disease-causing Viruses to Attack Tumors
Patients Win When Cancer Researchers Share Data
Targeted Therapy Highlights, ASCO 2004
Cetuximab Improves Locoregional Control and Overall Survival in Head & Neck Cancer
Modestly Increased Survival Seen with Erlotinib in Advanced NSCLC
Combining Targeted Therapies: Early-Phase Studies with Bevacizumab Plus Erlotinib
Understanding Patient Responsiveness to Gefitinib
Good Results Start with a Robust Target
Four Targeted Cancer Therapies Approved in Early 2004
Other News
The First EGFR Inhibitor in Clinical Use
Selecting Patients for Targeted Therapies
From the 26th Annual San Antonio Breast Cancer Symposium
New Radiation Labeling Technique Improves Therapeutic Effectiveness of Humanized Antitumor Antibody
Theratope Vaccine: Subgroup Analysis Suggests Immune Response Takes Time
From the 45th Annual Meeting of the American Society of Hematology
Bcl-2 Blocker Enhances Activity of Anticancer Agents Against Many Tumors
Novel Dual Selective Src/Abl Inhibitor Shows Promise for Treatment of Imatinib-Resistant Leukemia
Gene-based Diagnostics: At the Intersection of Pharmaceuticals and Genomics
Attacking Tumors on Multiple Fronts
NCI Joins Effort to Explore Safety and Effectiveness of Antisense Drug
Encouraging Results Reported for Antigastrin-Targeted Immunotherapy for Pancreatic Cancer
Nonmyeloablative Conditioning Allows Transplanted Killer T Cells to Flourish
Targeted Agents as Auxilliary Weapons
News from the 39th Meeting of the American Society of Clinical Oncology
First Report of Survival Advantage with Angiogenesis Inhibitor
Evidence of Immune Responses to STn-Vaccine Not Compromised by Concurrent Chemotherapy
Epidermal Growth Factor Receptor (EGFR) Inhibitors
An Antiangiogenic Vaccine—Targeting Tumor Vasculature
Targeted Therapies: The Challenge of Clinical Development
Early-Phase Testing of Vaccines for Common Malignancies Under Way in 2003
Trial of CEA-Targeted MAb Fails to Show Significant Survival Difference
Vol 4, No 3 | September 2006
Vol 4, No 2 | May/June 2006
Vol 4, No 1 | March/April 2006
Vol 3, No 3 | September/October 2005
Vol 3, No 2 | July/August 2005
Vol 3, No 1 | April/May 2005
Vol 2, No 3 | October/November 2004
Vol 2, No 2 | July/August 2004
Vol 2, No 1 | April/May 2004
Vol 1, No 4 | January/February 2004
Vol 1, No 3 | November/December 2003
Vol 1, No 2 | July/August 2003
Vol 1, No 1 | May 2003
Click to jump to issue Table of Contents.
